KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Invested Capital (2016 - 2025)

Inovio Pharmaceuticals' Invested Capital history spans 16 years, with the latest figure at $42.7 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 41.99% year-over-year to $42.7 million; the TTM value through Sep 2025 reached $42.7 million, down 41.99%, while the annual FY2024 figure was $81.8 million, 39.04% down from the prior year.
  • Invested Capital for Q3 2025 was $42.7 million at Inovio Pharmaceuticals, up from $40.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $582.4 million in Q1 2021 and bottomed at $40.0 million in Q2 2025.
  • The 5-year median for Invested Capital is $186.1 million (2023), against an average of $224.1 million.
  • The largest annual shift saw Invested Capital soared 209.58% in 2021 before it plummeted 58.7% in 2025.
  • A 5-year view of Invested Capital shows it stood at $400.2 million in 2021, then tumbled by 44.44% to $222.4 million in 2022, then crashed by 39.68% to $134.1 million in 2023, then tumbled by 39.04% to $81.8 million in 2024, then crashed by 47.82% to $42.7 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Invested Capital are $42.7 million (Q3 2025), $40.0 million (Q2 2025), and $60.8 million (Q1 2025).